GlassScriptPhysician profile
Hannah Fordred
NPI 1730558172
$8,354.01
in general payments reported to CMS, 2019-2025
65 companies · $2,573 in 2025
The $2,573 reported for 2025 was more than what 94% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $111 · 2022: $1,726 · 2023: $1,625 · 2024: $2,319 · 2025: $2,573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,147 · Consulting Fee: $280 · Education: $89.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,147.04 |
| Consulting Fee | $280.00 |
| Education | $89.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $749.74 | 2022-2025 | Reblozyl, Pomalyst |
| Novartis Pharmaceuticals Corporation | $640.97 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $561.90 | 2022-2025 | Lynparza, Calquence, Imfinzi |
| Janssen Biotech, INC. | $523.12 | 2021-2025 | Balversa, Erleada, Talvey |
| E.R. Squibb & Sons, L.L.C. | $421.83 | 2022-2025 | Opdivo, Krazati, Opdualag |
| Regeneron Healthcare Solutions, INC. | $389.77 | 2022-2025 | Libtayo |
| Daiichi Sankyo INC. | $348.42 | 2022-2025 | Enhertu, Datroway, Injectafer |
| Incyte Corporation | $339.55 | 2021-2025 | Jakafi, Monjuvi, Zynyz |
| Genzyme Corporation | $279.03 | 2022-2025 | |
| Abbvie INC. | $277.47 | 2022-2025 | |
| Beigene USA, INC. | $224.19 | 2022-2025 | Brukinsa |
| Eisai INC. | $215.91 | 2022-2025 | |
| Astellas Pharma US INC | $173.63 | 2023-2025 | Veozah, Padcev, Vyloy |
| Array Biopharma INC | $162.41 | 2022-2025 | Braftovi, Mektovi, Tukysa |
| Genentech USA, INC. | $159.53 | 2021-2025 | Polivy, Columvi, Lunsumio |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $154.71 | 2022-2025 | Ninlaro, Fruzaqla, Iclusig |
| Lilly USA, LLC | $150.59 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Jazz Pharmaceuticals INC. | $146.59 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $138.53 | 2022-2025 | Onivyde, Somatuline Depot |
| Pharmacosmos Therapeutics INC. | $135.28 | 2022-2025 | Monoferric, Cosela |
| Glaxosmithkline, LLC. | $113.68 | 2022-2025 | Ojjaara, Jemperli, Zejula |
| Aveo Pharmaceuticals, INC. | $113.29 | 2022-2025 | Fotivda |
| Beone Medicines USA, INC. | $101.65 | 2025 | Brukinsa, Tevimbra |
| Pfizer INC. | $98.43 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.63 | 2022-2025 | |
| Emd Serono, INC. | $85.96 | 2024-2025 | |
| G1 Therapeutics, INC. | $77.16 | 2022-2023 | Cosela |
| Octapharma USA, INC. | $68.97 | 2022-2024 | Octagam Immune Globulin (Human) |
| Tersera Therapeutics LLC | $68.90 | 2022-2025 | Quzyttir |
| Karyopharm Therapeutics INC. | $68.62 | 2022-2023 | Xpovio |
| Novocure INC. | $68.44 | 2024-2025 | Optune Gio, Optune Lua (Novottf-200t), Optune |
| Mirati Therapeutics, INC. | $66.67 | 2023-2024 | Krazati |
| Sobi, INC | $64.08 | 2024-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $64.04 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.93 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $62.70 | 2022-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Csl Behring | $55.36 | 2023 | Idelvion, Afstyla |
| Pharmaessentia USA Corporation | $52.99 | 2025 | Besremi |
| Stemline Therapeutics INC. | $50.70 | 2024-2025 | Orserdu |
| Deciphera Pharmaceuticals INC. | $48.49 | 2022-2025 | Romvimza, Qinlock |
| Myriad Genetic Laboratories, INC. | $40.05 | 2022-2025 | Myrisk |
| Tempus Ai, INC | $38.59 | 2025 | Xt Cdx |
| Amneal Pharmaceuticals LLC | $38.09 | 2025 | Alymsys |
| Servier Pharmaceuticals LLC | $37.26 | 2022-2025 | |
| Coherus Oncology, INC. | $36.58 | 2022 | |
| Morphosys, US INC. | $36.48 | 2022-2023 | Monjuvi |
| Seagen INC. | $36.41 | 2022 | |
| Progenics Pharmaceuticals, INC. | $35.84 | 2024-2025 | |
| Caris Mpi, INC. | $35.16 | 2025 | Mi Cancer Seek |
| Rigel Pharmaceuticals, INC. | $33.57 | 2023-2024 | Tavalisse, Rezlidhia |
| Dendreon Pharmaceuticals LLC | $33.12 | 2024 | Provenge |
| Apellis Pharmaceuticals, INC. | $30.13 | 2024 | Empaveli |
| Eusa Pharma (US) LLC | $28.79 | 2022 | |
| Blueprint Medicines Corporation | $27.28 | 2022 | |
| Heron Therapeutics, INC. | $27.22 | 2022 | |
| Agios Pharmaceuticals, INC. | $21.02 | 2025 | Pyrukynd |
| Puma Biotechnology, INC. | $19.92 | 2023 | Nerlynx |
| Genmab U.S., INC. | $18.11 | 2023 | Epkinly |
| Exelixis INC. | $17.83 | 2023 | Cabometyx |
| Immunogen, INC. | $17.68 | 2024 | Elahere |
| Adc Therapeutics America, INC. | $16.81 | 2023 | |
| Immunocore Limited | $14.52 | 2024 | Kimmtrak |
| Sumitomo Pharma America, INC. | $13.75 | 2023 | Orgovyx |
| Iovance Biotherapeutics, INC. | $13.19 | 2025 | Amtagvi |
| Global Blood Therapeutics, INC. | $12.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Fordred listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.